A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms Patiromer JADE
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 25 Nov 2024 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2025.
- 19 Sep 2024 Planned End Date changed from 1 Nov 2026 to 1 Dec 2026.
- 19 Sep 2024 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.